Metastatic Castration-resistent Prostate Cancer
1 clinical trials · Condition
◉ Watch Metastatic Castration-resistent Prostate Cancer
| Record | Firm | Date |
|---|---|---|
| Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide. (NCT04139772) | National Cancer Institute, Naples | 2019-09-01 |
Track Metastatic Castration-resistent Prostate Cancer automatically
Every clearance here is in the API, with alerts when new ones post.